DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study.
DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study.
复制标题
DOI：
10.1097/jcp.0b013e318267b6da
复制
发表时间：
2012-10
影响因子：
2.9
通讯作者：
S. Tsuchimine;N. Yasui‐Furukori;T. Nakagami;Yasushi Sato;S. Kaneko
中科院分区：
文献类型：
--
作者：
S. Tsuchimine;N. Yasui‐Furukori;T. Nakagami;Yasushi Sato;S. Kaneko
编者按：严重抑郁障碍(MDD)通常使用针对5-羟色胺转运体的抗抑郁药物治疗；然而，只有50%至70%的患者对这种治疗有反应。最近的一项研究表明，脑源性神经营养因子(BDNF)的增加是抗抑郁药物诱导伏隔核多巴胺超敏反应，导致多巴胺D3受体(DRD3)基因转录增加的原因。1Y3因此，DRD3和BDNF都可能影响抗抑郁药物治疗的药物基因组学。一些研究已经调查了BDNF基因Val66Met多态与抗抑郁反应之间的关系，而很少有研究调查DRD3多态对抗抑郁反应的潜在影响
To the Editors: Major depressive disorder (MDD) is typically treated with antidepressants that target the serotonin transporter; however, only 50% to 70% of patients respond to this type of treatment. A recent study suggests that increased delivery of brainderived neurotrophic factor (BDNF) accounts for antidepressant-induced dopamine supersensitivity in the nucleus accumbens, resulting in increased dopamine D3 receptor (DRD3) gene transcription. 1Y3 Therefore, both DRD3 and BDNF may affect the pharmacogenomics of antidepressant treatments. Several studies have investigated an association between the Val66Met polymorphism of the BDNF gene with the antidepressant response, whereas few studies have investigated potential effects on the antidepressant response of polymorphisms of the DRD3